Identification

Name
Ibandronate
Accession Number
DB00710  (APRD00231, DB04635)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Structure
Thumb
Synonyms
  • Ibandronic Acid
External IDs
R484
Product Ingredients
IngredientUNIICASInChI Key
Ibandronate sodium23Y0B94E49138926-19-9LXLBEOAZMZAZND-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BondronatLiquid1 mgIntravenousHoffmann La Roche2004-05-312006-05-17Canada
BonivaTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2005-06-02Not applicableUs
BonivaInjection, solution3 mg/3mLIntravenousGenentech, Inc.2011-06-01Not applicableUs
BonivaTablet, film coated150 mg/1OralGenentech, Inc.2002-07-15Not applicableUs
BonvivaInjection, solution3 mgIntravenousAtnahs Pharma Uk Limited2004-02-23Not applicableEu
BonvivaTablet, film coated150 mgOralAtnahs Pharma Uk Limited2004-02-23Not applicableEu
BonvivaInjection, solution3 mgIntravenousAtnahs Pharma Uk Limited2004-02-23Not applicableEu
BonvivaTablet, film coated150 mgOralAtnahs Pharma Uk Limited2004-02-23Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate2 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate1 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BondenzaIbandronate (150 mg)Tablet, film coatedOralRoche Registration Limited2004-02-232013-05-13Eu
BondenzaIbandronate (3 mg)Injection, solutionIntravenousRoche Registration Limited2004-02-232013-05-13Eu
BondenzaIbandronate (150 mg)Tablet, film coatedOralRoche Registration Limited2004-02-232013-05-13Eu
BondenzaIbandronate (3 mg)Injection, solutionIntravenousRoche Registration Limited2004-02-232013-05-13Eu
International/Other Brands
ADRONiL / Bondronat / Bonviva
Categories
UNII
UMD7G2653W
CAS number
114084-78-5
Weight
Average: 319.2289
Monoisotopic: 319.094975119
Chemical Formula
C9H23NO7P2
InChI Key
MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
IUPAC Name
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
SMILES
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions
Pharmacodynamics

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Mechanism of action

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Human
AHydroxylapatite
antagonist
Human
Absorption

Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.

Volume of distribution
  • 90 L
Protein binding

90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL

Metabolism

No evidence of ibandronate being metabolized in humans.

Route of elimination

Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.

Half life

10-60 hours

Clearance
  • 84 to 160 mL/min [IV administration]
Toxicity

LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibandronate Action PathwayDrug action
Ibandronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbexinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat.Investigational
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate.Approved, Investigational
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Ibandronate.Approved, Experimental, Investigational
AceprometazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.Approved
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acrivastine.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Alcaftadine.Approved
AlclofenacThe risk or severity of gastrointestinal bleeding can be increased when Alclofenac is combined with Ibandronate.Approved, Withdrawn
Alendronic acidThe risk or severity of hypocalcemia can be increased when Ibandronate is combined with Alendronic acid.Approved
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibandronate.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Alimemazine.Approved, Vet Approved
AlmasilateThe serum concentration of Ibandronate can be decreased when it is combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Ibandronate.Experimental
AloglutamolThe serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol.Approved
AluminiumThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Aluminium clofibrate.Experimental
Aluminium glycinateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminium phosphateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmantadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amantadine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amifampridine.Approved
AmikacinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Ibandronate.Approved, Investigational, Vet Approved
AminophenazoneThe risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Ibandronate.Approved, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amitriptyline.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ibandronate.Approved
Amphotericin BThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Anagrelide.Approved
AnecortaveThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Ibandronate.Investigational
anecortave acetateThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when anecortave acetate is combined with Ibandronate.Investigational
AntazolineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Antazoline.Approved
AntipyrineThe risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Ibandronate.Approved, Investigational
AntrafenineThe risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Ibandronate.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Ibandronate.Experimental, Vet Approved
ArbekacinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Ibandronate.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole lauroxil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate.Approved
AtorvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Ibandronate.Withdrawn
AzatadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azatadine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azithromycin.Approved
AzosemideThe risk or severity of hypocalcemia can be increased when Azosemide is combined with Ibandronate.Investigational
BacitracinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Ibandronate.Approved, Vet Approved
BalsalazideThe risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bedaquiline.Approved
BekanamycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Bekanamycin is combined with Ibandronate.Experimental
BendazacThe risk or severity of gastrointestinal bleeding can be increased when Bendazac is combined with Ibandronate.Experimental
BenorilateThe risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Ibandronate.Experimental
BenoxaprofenThe risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Ibandronate.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Benzatropine.Approved
BenzydamineThe risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Ibandronate.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Besifloxacin.Approved
BevacizumabThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.Approved, Investigational
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Bezafibrate.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bilastine.Approved, Investigational
Bismuth subnitrateThe serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate.Approved
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate.Approved, Investigational
BromfenacThe risk or severity of gastrointestinal bleeding can be increased when Bromfenac is combined with Ibandronate.Approved
BrompheniramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Brompheniramine.Approved
BuclizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Buclizine.Approved
BufexamacThe risk or severity of gastrointestinal bleeding can be increased when Bufexamac is combined with Ibandronate.Approved, Experimental
BumadizoneThe risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Ibandronate.Experimental
BumetanideThe risk or severity of hypocalcemia can be increased when Bumetanide is combined with Ibandronate.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Buserelin.Approved, Investigational
ButriptylineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Butriptyline.Approved
Calcitonin porcineThe risk or severity of hypocalcemia can be increased when Calcitonin porcine is combined with Ibandronate.Experimental
Calcium AcetateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium levulinateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium levulinate.Approved, Experimental
Calcium pangamateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate.Experimental
CapreomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Ibandronate.Approved
Carbaspirin calciumThe risk or severity of gastrointestinal bleeding can be increased when Carbaspirin calcium is combined with Ibandronate.Experimental, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Carbinoxamine.Approved
CarboplatinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Ibandronate.Approved
CarprofenThe risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Ibandronate.Approved, Vet Approved, Withdrawn
CefacetrileThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefacetrile is combined with Ibandronate.Approved
CefaclorThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Ibandronate.Approved
CefadroxilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Ibandronate.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Ibandronate.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Ibandronate.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Ibandronate.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Ibandronate.Experimental
CefazedoneThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazedone is combined with Ibandronate.Experimental
CefazolinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Ibandronate.Approved
CefbuperazoneThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefbuperazone is combined with Ibandronate.Experimental
CefcapeneThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefcapene is combined with Ibandronate.Experimental
CefditorenThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Ibandronate.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Ibandronate.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Ibandronate.Experimental
CefmenoximeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmenoxime is combined with Ibandronate.Approved
CefmetazoleThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Ibandronate.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefminox is combined with Ibandronate.Approved
CefodizimeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Ibandronate.Experimental
CefonicidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Ibandronate.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Ibandronate.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Ibandronate.Approved
CefotaximeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Ibandronate.Approved
CefotetanThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Ibandronate.Approved
CefotiamThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Ibandronate.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Ibandronate.Approved
CefozopranThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefozopran is combined with Ibandronate.Experimental
CefpiramideThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpiramide is combined with Ibandronate.Approved
CefpiromeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Ibandronate.Approved
CefpodoximeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Ibandronate.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Ibandronate.Approved
CefradineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Ibandronate.Approved
CefroxadineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefroxadine is combined with Ibandronate.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Ibandronate.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Ibandronate.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Ibandronate.Approved
CeftezoleThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftezole is combined with Ibandronate.Experimental
CeftibutenThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Ibandronate.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Ibandronate.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftobiprole is combined with Ibandronate.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Ibandronate.Approved
CefuroximeThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Ibandronate.Approved
CelecoxibThe risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Ibandronate.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloglycin is combined with Ibandronate.Approved
CephaloridineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloridine is combined with Ibandronate.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalothin Group is combined with Ibandronate.Experimental
CeritinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib.Approved
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Cerivastatin.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cetirizine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorcyclizine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Ibandronate.Approved
CilostazolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cilostazol.Approved, Investigational
CimicoxibThe risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Ibandronate.Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clemastine.Approved, Investigational
Clodronic AcidThe risk or severity of hypocalcemia can be increased when Clodronic Acid is combined with Ibandronate.Approved, Investigational, Vet Approved
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Clofibride.Experimental
ClomipramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Ibandronate.Approved
ClozapineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cocaine.Approved, Illicit
ColistimethateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Ibandronate.Approved, Vet Approved
CrizotinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC-907.Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cyclizine.Approved
CyclosporineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cyproheptadine.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib.Approved, Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Ibandronate is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Delamanid.Approved, Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desflurane.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desloratadine.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine maleate.Approved
DexibuprofenThe risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Ibandronate.Approved, Investigational
DexketoprofenThe risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Ibandronate.Approved, Investigational
DexlansoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.Approved, Investigational
DexrabeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole.Experimental
DibekacinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Dibekacin is combined with Ibandronate.Experimental
DiclofenacThe risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Ibandronate.Approved, Vet Approved
DifenpiramideThe risk or severity of gastrointestinal bleeding can be increased when Difenpiramide is combined with Ibandronate.Experimental
DifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Difloxacin.Vet Approved
DiflunisalThe risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Ibandronate.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Ibandronate.Investigational, Vet Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diphenhydramine.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Donepezil.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dosulepin.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxepin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxylamine.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Droperidol.Approved, Vet Approved
DroxicamThe risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Ibandronate.Withdrawn
EbastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ebastine.Approved, Investigational
ElcatoninThe risk or severity of hypocalcemia can be increased when Elcatonin is combined with Ibandronate.Experimental
EliglustatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Emedastine.Approved
EndostatinThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Ibandronate.Investigational
EnoxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entinostat.Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Epinastine.Approved, Investigational
EpirizoleThe risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Ibandronate.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Escitalopram.Approved, Investigational
EsomeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
Etacrynic acidThe risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate.Approved, Investigational
EthenzamideThe risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Ibandronate.Experimental
Etidronic acidThe risk or severity of hypocalcemia can be increased when Etidronic acid is combined with Ibandronate.Approved
EtodolacThe risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Ibandronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Ibandronate.Approved, Investigational
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Etofibrate.Approved
EtoricoxibThe risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Ibandronate.Approved, Investigational
EzogabineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felbamate.Approved
FelbinacThe risk or severity of gastrointestinal bleeding can be increased when Felbinac is combined with Ibandronate.Experimental
FenbufenThe risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Ibandronate.Approved
FenofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibric acid.Approved
FenoprofenThe risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Ibandronate.Approved
FentiazacThe risk or severity of gastrointestinal bleeding can be increased when Fentiazac is combined with Ibandronate.Experimental
FeprazoneThe risk or severity of gastrointestinal bleeding can be increased when Feprazone is combined with Ibandronate.Experimental
Ferric ammonium citrateFerric ammonium citrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationFerric cation can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideFerric hydroxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideFerric oxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric subsulfateFerric subsulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateFerric sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateFerrous bisglycinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideFerrous chloride can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateFerrous fumarate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateFerrous gluconate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateFerrous succinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateFerrous sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesFerumoxides can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilFerumoxsil can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fingolimod.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Ibandronate.Experimental, Vet Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Ibandronate.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Flomoxef is combined with Ibandronate.Investigational
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ibandronate.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of gastrointestinal bleeding can be increased when Flunixin is combined with Ibandronate.Vet Approved
FlunoxaprofenThe risk or severity of gastrointestinal bleeding can be increased when Flunoxaprofen is combined with Ibandronate.Experimental
FluorouracilThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flupentixol.Approved, Investigational, Withdrawn
FlurbiprofenThe risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Ibandronate.Approved, Investigational
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Fluvastatin.Approved
FormoterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Formoterol.Approved, Investigational
FoscarnetThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Ibandronate.Approved
FramycetinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Ibandronate.Approved
FumagillinThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Ibandronate.Experimental
FurosemideThe risk or severity of hypocalcemia can be increased when Furosemide is combined with Ibandronate.Approved, Vet Approved
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibandronate.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gatifloxacin.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Geneticin is combined with Ibandronate.Experimental
GentamicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Ibandronate.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity and hypocalcemia can be increased when GENTAMICIN C1A is combined with Ibandronate.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Givinostat.Investigational
GleptoferronGleptoferron can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of gastrointestinal bleeding can be increased when Guacetisal is combined with Ibandronate.Experimental
HalofantrineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Halofantrine.Approved
HalofuginoneThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate.Investigational, Vet Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Histrelin.Approved
Human calcitoninThe risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Ibandronate.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrolyzed Cephalothin is combined with Ibandronate.Experimental
HydrotalciteThe serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxychloroquine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ibandronate.Approved
Hygromycin BThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Ibandronate.Vet Approved
IbuprofenThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate.Approved
IbuproxamThe risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Ibandronate.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ibutilide.Approved
IcosapentThe risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Ibandronate.Approved, Nutraceutical
IloperidoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Ibandronate.Experimental
ImipramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine.Approved
Incadronic acidThe risk or severity of hypocalcemia can be increased when Ibandronate is combined with Incadronic acid.Approved, Investigational
IndacaterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indacaterol.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indapamide.Approved
IndobufenThe risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Ibandronate.Investigational
IndomethacinThe risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate.Approved, Investigational
IndoprofenThe risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Ibandronate.Withdrawn
Iron isomaltoside 1000Iron isomaltoside 1000 can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateIron saccharate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsepamicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Isepamicin is combined with Ibandronate.Experimental
IsofluraneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Isoflurane.Approved, Vet Approved
IsoxicamThe risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Ibandronate.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Ibandronate.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Itraconazole.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Ibandronate.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Ibandronate.Experimental
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Ibandronate.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketotifen.Approved
LansoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lapatinib.Approved, Investigational
LatamoxefThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Ibandronate.Approved, Investigational
LenalidomideThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Ibandronate.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Leuprolide.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocetirizine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levomethadyl Acetate.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lithium cation.Experimental
LomefloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Ibandronate.Experimental
LopinavirThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lopinavir.Approved
LoracarbefThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Ibandronate.Investigational, Withdrawn
LoratadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Ibandronate.Approved, Investigational
LovastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Ibandronate.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Ibandronate.Approved, Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Macimorelin.Approved, Investigational
MagaldrateThe serum concentration of Ibandronate can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Ibandronate.Approved
Magnesium silicateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium silicate.Approved
Magnesium sulfateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Ibandronate.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline.Approved, Investigational
Meclofenamic acidThe risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Ibandronate.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Ibandronate.Approved, Investigational
MeloxicamThe risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mequitazine.Approved
MesalazineThe risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mesoridazine.Approved, Investigational
MetamizoleThe risk or severity of gastrointestinal bleeding can be increased when Metamizole is combined with Ibandronate.Approved, Investigational, Withdrawn
MethadoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methadone.Approved
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methotrimeprazine.Approved, Investigational
MetoclopramideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metoclopramide.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metronidazole.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Mevastatin.Experimental
MicronomicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Micronomicin is combined with Ibandronate.Experimental
MifepristoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mifepristone.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mirabegron.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Ibandronate.Approved
MocetinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mocetinostat.Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Ibandronate.Approved
MofebutazoneThe risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Ibandronate.Experimental
MorniflumateThe risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Ibandronate.Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.Approved, Investigational
NabumetoneThe risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Ibandronate.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate.Approved, Vet Approved
NeamineThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Ibandronate.Experimental
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ibandronate.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Ibandronate.Approved, Vet Approved
NepafenacThe risk or severity of gastrointestinal bleeding can be increased when Nepafenac is combined with Ibandronate.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Ibandronate.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ibandronate.Approved, Investigational
NifenazoneThe risk or severity of gastrointestinal bleeding can be increased when Nifenazone is combined with Ibandronate.Experimental
Niflumic AcidThe risk or severity of gastrointestinal bleeding can be increased when Niflumic Acid is combined with Ibandronate.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Ibandronate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of gastrointestinal bleeding can be increased when Nitroaspirin is combined with Ibandronate.Investigational
NitroprussideNitroprusside can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NorfloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Norfloxacin.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ibandronate.Approved
NS-398The risk or severity of gastrointestinal bleeding can be increased when NS-398 is combined with Ibandronate.Experimental
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ibandronate.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olodaterol.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olopatadine.Approved
OlsalazineThe risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Ibandronate.Approved
OmeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ondansetron.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orbifloxacin.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orphenadrine.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin.Approved, Investigational
OxaprozinThe risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Ibandronate.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxolinic acid.Experimental
OxyphenbutazoneThe risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Ibandronate.Approved, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone.Approved
PamidronateThe risk or severity of hypocalcemia can be increased when Pamidronate is combined with Ibandronate.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Panobinostat.Approved, Investigational
PantoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Ibandronate.Approved
ParomomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Ibandronate.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pasireotide.Approved
PazopanibThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Ibandronate.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pefloxacin.Approved
PentamidineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pentamidine.Approved, Investigational
PerflubutanePerflubutane can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Perflutren.Approved
PheniramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pheniramine.Approved
PhenylbutazoneThe risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Ibandronate.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pimozide.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pipemidic acid.Experimental
PiretanideThe risk or severity of hypocalcemia can be increased when Piretanide is combined with Ibandronate.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
PirprofenThe risk or severity of gastrointestinal bleeding can be increased when Pirprofen is combined with Ibandronate.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Pitavastatin.Approved
PitolisantThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Ibandronate.Approved, Investigational
PomalidomideThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Posaconazole.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pracinostat.Investigational
PranoprofenThe risk or severity of gastrointestinal bleeding can be increased when Pranoprofen is combined with Ibandronate.Experimental, Investigational
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Pravastatin.Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Primaquine.Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Procainamide.Approved
ProglumetacinThe risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Ibandronate.Experimental
PromazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of gastrointestinal bleeding can be increased when Propacetamol is combined with Ibandronate.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone.Approved
PropofolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propofol.Approved, Investigational, Vet Approved
PropyphenazoneThe risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Ibandronate.Experimental
ProquazoneThe risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Ibandronate.Experimental
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ibandronate.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prulifloxacin.Investigational
Prussian bluePrussian blue can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PuromycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Ibandronate.Experimental
QuetiapineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinine.Approved
RabeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
RanibizumabThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Ibandronate.Approved, Investigational
ResveratrolThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Ibandronate.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Ibandronate.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rilpivirine.Approved
RisedronateThe risk or severity of hypocalcemia can be increased when Risedronate is combined with Ibandronate.Approved, Investigational
RisperidoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Risperidone.Approved, Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ibandronate.Approved, Investigational
RobenacoxibThe risk or severity of gastrointestinal bleeding can be increased when Robenacoxib is combined with Ibandronate.Experimental, Vet Approved
RofecoxibThe risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Ibandronate.Approved, Investigational, Withdrawn
RomidepsinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ronifibrate.Experimental
RoquinimexThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Ibandronate.Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rupatadine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Ibandronate.Approved
Salicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Ibandronate.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salmeterol.Approved
Salmon CalcitoninThe risk or severity of hypocalcemia can be increased when Salmon Calcitonin is combined with Ibandronate.Approved, Investigational
SalsalateThe risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sarafloxacin.Vet Approved, Withdrawn
SC-236The risk or severity of gastrointestinal bleeding can be increased when SC-236 is combined with Ibandronate.Experimental, Investigational
SemaxanibThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Ibandronate.Investigational
SertralineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sevoflurane.Approved, Vet Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Simvastatin.Approved
SisomicinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Ibandronate.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe serum concentration of Ibandronate can be decreased when it is combined with Sodium bicarbonate.Approved
Sodium feredetateSodium feredetate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SolifenacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Solifenacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ibandronate.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sparfloxacin.Approved, Investigational
SqualamineThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Ibandronate.Investigational
StreptomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Ibandronate.Approved, Vet Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sultopride.Experimental
SunitinibThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Ibandronate.Approved, Investigational
SuprofenThe risk or severity of gastrointestinal bleeding can be increased when Suprofen is combined with Ibandronate.Approved, Withdrawn
SuxibuzoneThe risk or severity of gastrointestinal bleeding can be increased when Suxibuzone is combined with Ibandronate.Experimental
TalniflumateThe risk or severity of gastrointestinal bleeding can be increased when Talniflumate is combined with Ibandronate.Approved
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ibandronate.Approved
TandutinibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tandutinib.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Technetium Tc-99m ciprofloxacin.Investigational
Technetium Tc-99m oxidronateThe risk or severity of hypocalcemia can be increased when Ibandronate is combined with Technetium Tc-99m oxidronate.Approved
TelavancinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of gastrointestinal bleeding can be increased when Tenidap is combined with Ibandronate.Experimental
TenofovirThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Ibandronate.Experimental, Investigational
Tenofovir alafenamideThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Ibandronate.Approved
Tenofovir disoproxilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Ibandronate.Approved, Investigational
TenoxicamThe risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Ibandronate.Approved
TepoxalinThe risk or severity of gastrointestinal bleeding can be increased when Tepoxalin is combined with Ibandronate.Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tetrabenazine.Approved, Investigational
Tetraferric tricitrate decahydrateTetraferric tricitrate decahydrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThalidomideThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Ibandronate.Approved, Investigational, Withdrawn
ThioridazineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thiothixene.Approved
Tiaprofenic acidThe risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Ibandronate.Approved
Tiludronic acidThe risk or severity of hypocalcemia can be increased when Ibandronate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineThe risk or severity of gastrointestinal bleeding can be increased when Tinoridine is combined with Ibandronate.Investigational
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ibandronate.Approved, Investigational
TobramycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Ibandronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Ibandronate.Approved, Investigational
TolmetinThe risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Ibandronate.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tolterodine.Approved, Investigational
TorasemideThe risk or severity of hypocalcemia can be increased when Torasemide is combined with Ibandronate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Toremifene.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibandronate.Approved, Investigational
TrebananibThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ibandronate.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Ibandronate.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin.Approved, Vet Approved
Trolamine salicylateThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Ibandronate.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tucidinostat.Investigational
ValdecoxibThe risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Ibandronate.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Ibandronate.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vardenafil.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ibandronate.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vilanterol.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ibandronate.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vorinostat.Approved, Investigational
ZaltoprofenThe risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Ibandronate.Approved, Investigational
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of hypocalcemia can be increased when Zoledronic acid is combined with Ibandronate.Approved
ZomepiracThe risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Ibandronate.Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.

References

Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

US20070179119
General References
  1. Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205]
External Links
Human Metabolome Database
HMDB0014848
PubChem Compound
60852
PubChem Substance
46508134
ChemSpider
54839
BindingDB
12577
ChEMBL
CHEMBL997
Therapeutic Targets Database
DAP001022
PharmGKB
PA10270
HET
BFQ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibandronate
ATC Codes
M05BA06 — Ibandronic acid
PDB Entries
2f94 / 4umj
FDA label
Download (296 KB)
MSDS
Download (16 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentOsteoporosis, Post-Menopausal1
2CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis1
2RecruitingTreatmentBone destruction1
2Unknown StatusTreatmentCancer, Breast1
2WithdrawnTreatmentBone Neoplasms / Neoplasms Metastasis / Pain1
2, 3CompletedTreatmentBone destruction1
2, 3Unknown StatusTreatmentTransplant, Kidney1
3Active Not RecruitingTreatmentCancer, Breast1
3CompletedSupportive CareMetastatic Cancers / Pain / Prostate Cancer1
3CompletedTreatmentBone Marrow Edema of the Knee / Osteonecrosis of the Knee1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentHaematological Malignancies1
3CompletedTreatmentMale Osteoporosis1
3CompletedTreatmentOsteoporosis, Post-Menopausal1
3CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
3CompletedTreatmentPost Menopausal Osteoporosis3
3CompletedTreatmentPost-Menopausal Osteopenia1
3CompletedTreatmentPostmenopausal Osteoporosis (PMO)2
3CompletedTreatmentPostmenopausal Women With Osteoporosis1
3CompletedTreatmentPrimary Osteoporosis1
3CompletedTreatmentBone destruction1
3TerminatedTreatmentAseptic / Aseptic Hip Necrosis / Hip Necrosis1
3TerminatedTreatmentBone Neoplasms / Neoplasms Metastasis / Pain2
3TerminatedTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentCancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers1
3WithdrawnSupportive CareCancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers / Pain1
4CompletedPreventionBone destruction / Osteopenia / Rheumatoid Arthritis1
4CompletedTreatmentOsteoporosis, Post-Menopausal3
4CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
4CompletedTreatmentPost Menopausal Osteoporosis5
4CompletedTreatmentPost-Menopausal Osteopenia1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)8
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4CompletedTreatmentBone destruction3
4No Longer AvailableNot AvailablePostmenopausal Osteoporosis (PMO)1
4SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentLung Cancers1
4TerminatedTreatmentBone destruction1
Not AvailableCompletedNot AvailableAdenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableCompletedNot AvailablePostmenopausal Osteoporosis (PMO)1
Not AvailableCompletedNot AvailableBone destruction3
Not AvailableEnrolling by InvitationNot AvailableAtypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction1
Not AvailableWithdrawnNot AvailableCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
  • Diversified Healthcare Services Inc.
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • Physicians Total Care Inc.
  • Vetter Pharma Fertigung GmbH and Co. KG
Dosage forms
FormRouteStrength
Injection, solutionIntravenous3 mg
Tablet, film coatedOral150 mg
LiquidIntravenous1 mg
Tablet, film coatedOral150 mg/1
Injection, solution, concentrateIntravenous1 mg
Injection, solution, concentrateIntravenous2 mg
Injection, solution, concentrateIntravenous6 mg
Tablet, film coatedOral50 mg
InjectionIntravenous3 mg/3mL
Injection, solutionIntravenous3 mg/3mL
TabletOral150 mg/1
Prices
Unit descriptionCostUnit
Boniva 3 mg/3ml Kit Box524.22USD box
Boniva 3 mg/3 ml syringe504.06USD syringe
Boniva 3 150 mg tablet Disp Pack388.93USD disp
Boniva 150 mg tablet124.66USD tablet
Boniva 2.5 mg tablet4.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4927814No1995-03-172012-03-17Us
CA2346662No2006-05-092019-10-01Canada
US7192938Yes2003-11-062023-11-06Us
US7718634Yes2003-11-062023-11-06Us
US7410957No2003-05-062023-05-06Us
US6294196No1999-10-072019-10-07Us
US6143326No1997-04-212017-04-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityFreely solubleNot Available
logP-2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.4 mg/mLALOGPS
logP0.26ALOGPS
logP-2.5ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.66ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.53 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity71.16 m3·mol-1ChemAxon
Polarizability29.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9664
Blood Brain Barrier-0.5229
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.6888
P-glycoprotein inhibitor INon-inhibitor0.8195
P-glycoprotein inhibitor IINon-inhibitor0.9838
Renal organic cation transporterNon-inhibitor0.9092
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7863
CYP450 3A4 substrateNon-substrate0.5504
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.8987
CYP450 2C19 inhibitorNon-inhibitor0.8045
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9945
Ames testNon AMES toxic0.6527
CarcinogenicityNon-carcinogens0.683
BiodegradationNot ready biodegradable0.8346
Rat acute toxicity2.4278 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6061
hERG inhibition (predictor II)Non-inhibitor0.6622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359]
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:39